TP53 and cancer: Notably, higher numbers of cancer cells were associated with a stronger proliferative advantage of Tp53-deficient fibroblasts as compared to wild-type cells in line with the concept that loss of Tp53 heightens the sensitivity of mutant fibroblasts to epithelial-derived growth factors.